Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
19
GBLX Quote, Financials, Valuation and Earnings
Last price:
$0.0000
Seasonality move
:
-8.24%
Day range:
$0.0003 - $0.5002
52-week range:
$0.0000 - $0.5002
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.26x
P/B ratio:
--
Volume:
3.3K
Avg. volume:
19.3K
1-year change:
-88%
Market cap:
$122.1K
Revenue:
--
EPS (TTM):
-$0.00
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
GBLX
GB Sciences, Inc.
|
-- | -- | -- | -- | -- |
|
BSEM
BioStem Technologies, Inc.
|
$55.2M | $0.02 | -37.86% | -100% | $25.5000 |
|
IOVA
Iovance Biotherapeutics, Inc.
|
$81M | -$0.18 | 58.55% | -61.17% | $8.80 |
|
PKTX
Protokinetix, Inc.
|
-- | -- | -- | -- | -- |
|
PSTV
Plus Therapeutics, Inc.
|
$1.2M | -$0.04 | 22.78% | -97.49% | $5.50 |
|
TVTX
Travere Therapeutics, Inc.
|
$147.7M | $0.37 | 70.51% | -58.21% | $42.7143 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
GBLX
GB Sciences, Inc.
|
$0.0003 | -- | $122.1K | -- | $0.00 | 0% | 1.26x |
|
BSEM
BioStem Technologies, Inc.
|
$5.3600 | $25.5000 | $89.9M | 6.30x | $0.00 | 0% | 0.51x |
|
IOVA
Iovance Biotherapeutics, Inc.
|
$3.75 | $8.80 | $1.5B | -- | $0.00 | 0% | 5.08x |
|
PKTX
Protokinetix, Inc.
|
$0.0067 | -- | $2.6M | 23.85x | $0.00 | 0% | -- |
|
PSTV
Plus Therapeutics, Inc.
|
$0.30 | $5.50 | $41.2M | -- | $0.00 | 0% | 4.80x |
|
TVTX
Travere Therapeutics, Inc.
|
$29.5300 | $42.7143 | $2.7B | -- | $0.00 | 0% | 5.57x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
GBLX
GB Sciences, Inc.
|
-- | 5.767 | -- | -- |
|
BSEM
BioStem Technologies, Inc.
|
6.34% | -0.168 | 4.31% | 3.87x |
|
IOVA
Iovance Biotherapeutics, Inc.
|
6.61% | -2.426 | 4.4% | 2.74x |
|
PKTX
Protokinetix, Inc.
|
-- | 1.031 | -- | 0.00x |
|
PSTV
Plus Therapeutics, Inc.
|
0.41% | -3.087 | 0.02% | 1.22x |
|
TVTX
Travere Therapeutics, Inc.
|
74.11% | 0.721 | 9.46% | 2.52x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
GBLX
GB Sciences, Inc.
|
-- | -$157.8K | -- | -- | -- | -$107.7K |
|
BSEM
BioStem Technologies, Inc.
|
$9.2M | $1.4M | 44.01% | 48.25% | 13.83% | -- |
|
IOVA
Iovance Biotherapeutics, Inc.
|
$34.1M | -$73.5M | -50.85% | -54.64% | -84.79% | -$61.9M |
|
PKTX
Protokinetix, Inc.
|
-$12.6K | -$84.9K | -111.59% | -111.59% | -- | -$9.5K |
|
PSTV
Plus Therapeutics, Inc.
|
$1.3M | -$4.5M | -- | -- | -320.83% | -$2.6M |
|
TVTX
Travere Therapeutics, Inc.
|
$109M | -$32.4M | -11.56% | -80.28% | -25% | $41.8M |
GB Sciences, Inc. vs. Competitors
-
Which has Higher Returns GBLX or BSEM?
BioStem Technologies, Inc. has a net margin of -- compared to GB Sciences, Inc.'s net margin of 7.27%. GB Sciences, Inc.'s return on equity of -- beat BioStem Technologies, Inc.'s return on equity of 48.25%.
Company Gross Margin Earnings Per Share Invested Capital GBLXGB Sciences, Inc.-- -$0.00 -- BSEMBioStem Technologies, Inc.87.95% $0.03 $53.4M -
What do Analysts Say About GBLX or BSEM?
GB Sciences, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand BioStem Technologies, Inc. has an analysts' consensus of $25.5000 which suggests that it could grow by 375.75%. Given that BioStem Technologies, Inc. has higher upside potential than GB Sciences, Inc., analysts believe BioStem Technologies, Inc. is more attractive than GB Sciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GBLXGB Sciences, Inc.0 0 0 BSEMBioStem Technologies, Inc.0 0 0 -
Is GBLX or BSEM More Risky?
GB Sciences, Inc. has a beta of 11.460, which suggesting that the stock is 1045.961% more volatile than S&P 500. In comparison BioStem Technologies, Inc. has a beta of -0.050, suggesting its less volatile than the S&P 500 by 104.97%.
-
Which is a Better Dividend Stock GBLX or BSEM?
GB Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioStem Technologies, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GB Sciences, Inc. pays -- of its earnings as a dividend. BioStem Technologies, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GBLX or BSEM?
GB Sciences, Inc. quarterly revenues are --, which are smaller than BioStem Technologies, Inc. quarterly revenues of $10.5M. GB Sciences, Inc.'s net income of -$190.5K is lower than BioStem Technologies, Inc.'s net income of $761.1K. Notably, GB Sciences, Inc.'s price-to-earnings ratio is -- while BioStem Technologies, Inc.'s PE ratio is 6.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GB Sciences, Inc. is 1.26x versus 0.51x for BioStem Technologies, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GBLXGB Sciences, Inc.1.26x -- -- -$190.5K BSEMBioStem Technologies, Inc.0.51x 6.30x $10.5M $761.1K
-
Which has Higher Returns GBLX or IOVA?
Iovance Biotherapeutics, Inc. has a net margin of -- compared to GB Sciences, Inc.'s net margin of -82.92%. GB Sciences, Inc.'s return on equity of -- beat Iovance Biotherapeutics, Inc.'s return on equity of -54.64%.
Company Gross Margin Earnings Per Share Invested Capital GBLXGB Sciences, Inc.-- -$0.00 -- IOVAIovance Biotherapeutics, Inc.39.31% -$0.18 $748M -
What do Analysts Say About GBLX or IOVA?
GB Sciences, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Iovance Biotherapeutics, Inc. has an analysts' consensus of $8.80 which suggests that it could grow by 134.98%. Given that Iovance Biotherapeutics, Inc. has higher upside potential than GB Sciences, Inc., analysts believe Iovance Biotherapeutics, Inc. is more attractive than GB Sciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GBLXGB Sciences, Inc.0 0 0 IOVAIovance Biotherapeutics, Inc.6 3 0 -
Is GBLX or IOVA More Risky?
GB Sciences, Inc. has a beta of 11.460, which suggesting that the stock is 1045.961% more volatile than S&P 500. In comparison Iovance Biotherapeutics, Inc. has a beta of 0.690, suggesting its less volatile than the S&P 500 by 30.977%.
-
Which is a Better Dividend Stock GBLX or IOVA?
GB Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Iovance Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GB Sciences, Inc. pays -- of its earnings as a dividend. Iovance Biotherapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GBLX or IOVA?
GB Sciences, Inc. quarterly revenues are --, which are smaller than Iovance Biotherapeutics, Inc. quarterly revenues of $86.7M. GB Sciences, Inc.'s net income of -$190.5K is higher than Iovance Biotherapeutics, Inc.'s net income of -$71.9M. Notably, GB Sciences, Inc.'s price-to-earnings ratio is -- while Iovance Biotherapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GB Sciences, Inc. is 1.26x versus 5.08x for Iovance Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GBLXGB Sciences, Inc.1.26x -- -- -$190.5K IOVAIovance Biotherapeutics, Inc.5.08x -- $86.7M -$71.9M
-
Which has Higher Returns GBLX or PKTX?
Protokinetix, Inc. has a net margin of -- compared to GB Sciences, Inc.'s net margin of --. GB Sciences, Inc.'s return on equity of -- beat Protokinetix, Inc.'s return on equity of -111.59%.
Company Gross Margin Earnings Per Share Invested Capital GBLXGB Sciences, Inc.-- -$0.00 -- PKTXProtokinetix, Inc.-- -$0.00 $250.4K -
What do Analysts Say About GBLX or PKTX?
GB Sciences, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Protokinetix, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that GB Sciences, Inc. has higher upside potential than Protokinetix, Inc., analysts believe GB Sciences, Inc. is more attractive than Protokinetix, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GBLXGB Sciences, Inc.0 0 0 PKTXProtokinetix, Inc.0 0 0 -
Is GBLX or PKTX More Risky?
GB Sciences, Inc. has a beta of 11.460, which suggesting that the stock is 1045.961% more volatile than S&P 500. In comparison Protokinetix, Inc. has a beta of 0.654, suggesting its less volatile than the S&P 500 by 34.642%.
-
Which is a Better Dividend Stock GBLX or PKTX?
GB Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protokinetix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GB Sciences, Inc. pays -- of its earnings as a dividend. Protokinetix, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GBLX or PKTX?
GB Sciences, Inc. quarterly revenues are --, which are smaller than Protokinetix, Inc. quarterly revenues of --. GB Sciences, Inc.'s net income of -$190.5K is lower than Protokinetix, Inc.'s net income of -$84.9K. Notably, GB Sciences, Inc.'s price-to-earnings ratio is -- while Protokinetix, Inc.'s PE ratio is 23.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GB Sciences, Inc. is 1.26x versus -- for Protokinetix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GBLXGB Sciences, Inc.1.26x -- -- -$190.5K PKTXProtokinetix, Inc.-- 23.85x -- -$84.9K
-
Which has Higher Returns GBLX or PSTV?
Plus Therapeutics, Inc. has a net margin of -- compared to GB Sciences, Inc.'s net margin of -316.61%. GB Sciences, Inc.'s return on equity of -- beat Plus Therapeutics, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital GBLXGB Sciences, Inc.-- -$0.00 -- PSTVPlus Therapeutics, Inc.93.84% -$0.04 $5.1M -
What do Analysts Say About GBLX or PSTV?
GB Sciences, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $5.50 which suggests that it could grow by 1735.78%. Given that Plus Therapeutics, Inc. has higher upside potential than GB Sciences, Inc., analysts believe Plus Therapeutics, Inc. is more attractive than GB Sciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GBLXGB Sciences, Inc.0 0 0 PSTVPlus Therapeutics, Inc.4 0 0 -
Is GBLX or PSTV More Risky?
GB Sciences, Inc. has a beta of 11.460, which suggesting that the stock is 1045.961% more volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 0.788, suggesting its less volatile than the S&P 500 by 21.173%.
-
Which is a Better Dividend Stock GBLX or PSTV?
GB Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GB Sciences, Inc. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GBLX or PSTV?
GB Sciences, Inc. quarterly revenues are --, which are smaller than Plus Therapeutics, Inc. quarterly revenues of $1.4M. GB Sciences, Inc.'s net income of -$190.5K is higher than Plus Therapeutics, Inc.'s net income of -$4.4M. Notably, GB Sciences, Inc.'s price-to-earnings ratio is -- while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GB Sciences, Inc. is 1.26x versus 4.80x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GBLXGB Sciences, Inc.1.26x -- -- -$190.5K PSTVPlus Therapeutics, Inc.4.80x -- $1.4M -$4.4M
-
Which has Higher Returns GBLX or TVTX?
Travere Therapeutics, Inc. has a net margin of -- compared to GB Sciences, Inc.'s net margin of -16.95%. GB Sciences, Inc.'s return on equity of -- beat Travere Therapeutics, Inc.'s return on equity of -80.28%.
Company Gross Margin Earnings Per Share Invested Capital GBLXGB Sciences, Inc.-- -$0.00 -- TVTXTravere Therapeutics, Inc.84.05% -$0.24 $443.6M -
What do Analysts Say About GBLX or TVTX?
GB Sciences, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Travere Therapeutics, Inc. has an analysts' consensus of $42.7143 which suggests that it could grow by 44.65%. Given that Travere Therapeutics, Inc. has higher upside potential than GB Sciences, Inc., analysts believe Travere Therapeutics, Inc. is more attractive than GB Sciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GBLXGB Sciences, Inc.0 0 0 TVTXTravere Therapeutics, Inc.12 2 0 -
Is GBLX or TVTX More Risky?
GB Sciences, Inc. has a beta of 11.460, which suggesting that the stock is 1045.961% more volatile than S&P 500. In comparison Travere Therapeutics, Inc. has a beta of 0.809, suggesting its less volatile than the S&P 500 by 19.117%.
-
Which is a Better Dividend Stock GBLX or TVTX?
GB Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Travere Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GB Sciences, Inc. pays -- of its earnings as a dividend. Travere Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GBLX or TVTX?
GB Sciences, Inc. quarterly revenues are --, which are smaller than Travere Therapeutics, Inc. quarterly revenues of $129.7M. GB Sciences, Inc.'s net income of -$190.5K is higher than Travere Therapeutics, Inc.'s net income of -$22M. Notably, GB Sciences, Inc.'s price-to-earnings ratio is -- while Travere Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GB Sciences, Inc. is 1.26x versus 5.57x for Travere Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GBLXGB Sciences, Inc.1.26x -- -- -$190.5K TVTXTravere Therapeutics, Inc.5.57x -- $129.7M -$22M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
47
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 37x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
34
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
54
KORU alert for Mar 4
Direxion Daily MSCI South Korea Bull 3X Shares [KORU] is down 31.47% over the past day.
Sell
30
HROW alert for Mar 4
Harrow, Inc. [HROW] is down 27.92% over the past day.
Sell
28
GDXD alert for Mar 4
MicroSectors Gold Miners -3X Inverse Leveraged ETN [GDXD] is up 26.18% over the past day.
